Product Name: CEA Antibody [C66/1260]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC-P, WB
Applications: Flow Cytometry: 0.5-1 ug/million cells in 0.1mlImmunofluorescence: 1-2 ug/mlImmunohistochemistry (FFPE): 1-2 ug/ml for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)Optimal dilution of the CEA antibody to be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Purified human protein was used as the immunogen for the CEA antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 866405-64-3
Product: Dorsomorphin
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: CEACAM5 Antibody : CEA, CD66e, CEA, Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen
Accession NO.:
Protein Ino:
Official Symbol: CEACAM5
Geneid: 1048
Background: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family. CEA is synthesized during development in the fetal gut and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. This mAb reacts with nonspecific cross-reacting antigen (NCA). It shows no reaction with a variety of normal tissues and is suitable for staining of formalin/paraffin tissues. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and endocervix.
PubMed ID:http://aac.asm.org/content/35/10/1965.abstract
